KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Enterprise Value (2017 - 2026)

Aquestive Therapeutics has reported Enterprise Value over the past 9 years, most recently at -$121.2 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 69.36% year-over-year to -$121.2 million; the TTM value through Dec 2025 reached -$121.2 million, down 69.36%, while the annual FY2025 figure was -$121.2 million, 69.36% down from the prior year.
  • Enterprise Value for Q4 2025 was -$121.2 million at Aquestive Therapeutics, up from -$129.1 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$14.7 million in Q1 2022 and troughed at -$129.1 million in Q3 2025.
  • A 5-year average of -$50.6 million and a median of -$29.6 million in 2021 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: skyrocketed 48.31% in 2022 and later tumbled 300.56% in 2024.
  • Year by year, Enterprise Value stood at -$28.0 million in 2021, then rose by 2.68% to -$27.3 million in 2022, then grew by 12.47% to -$23.9 million in 2023, then crashed by 199.71% to -$71.5 million in 2024, then plummeted by 69.36% to -$121.2 million in 2025.
  • Business Quant data shows Enterprise Value for AQST at -$121.2 million in Q4 2025, -$129.1 million in Q3 2025, and -$60.5 million in Q2 2025.